KR870000277B1 - 피록시캄염의 제조방법 - Google Patents

피록시캄염의 제조방법 Download PDF

Info

Publication number
KR870000277B1
KR870000277B1 KR1019850007443A KR850007443A KR870000277B1 KR 870000277 B1 KR870000277 B1 KR 870000277B1 KR 1019850007443 A KR1019850007443 A KR 1019850007443A KR 850007443 A KR850007443 A KR 850007443A KR 870000277 B1 KR870000277 B1 KR 870000277B1
Authority
KR
South Korea
Prior art keywords
salt
pyroxycam
methyl
doxepin
pyridoxine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019850007443A
Other languages
English (en)
Korean (ko)
Other versions
KR860003248A (ko
Inventor
죠지 롬바르디노 조세프
Original Assignee
화이자 인코포레이티드
윌리암 데이비스 헌
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드, 윌리암 데이비스 헌 filed Critical 화이자 인코포레이티드
Publication of KR860003248A publication Critical patent/KR860003248A/ko
Application granted granted Critical
Publication of KR870000277B1 publication Critical patent/KR870000277B1/ko
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • C07D213/66One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C07D213/672-Methyl-3-hydroxy-4,5-bis(hydroxy-methyl)pyridine, i.e. pyridoxine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12[b,e]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1019850007443A 1984-10-11 1985-10-10 피록시캄염의 제조방법 Expired KR870000277B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US659,733 1984-10-11
US06/659,733 US4567179A (en) 1984-10-11 1984-10-11 Antiinflammatory salts of piroxicam

Publications (2)

Publication Number Publication Date
KR860003248A KR860003248A (ko) 1986-05-21
KR870000277B1 true KR870000277B1 (ko) 1987-02-23

Family

ID=24646598

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850007443A Expired KR870000277B1 (ko) 1984-10-11 1985-10-10 피록시캄염의 제조방법

Country Status (25)

Country Link
US (1) US4567179A (enExample)
EP (1) EP0178124B1 (enExample)
JP (1) JPS6193182A (enExample)
KR (1) KR870000277B1 (enExample)
CN (1) CN1008062B (enExample)
AT (1) ATE44147T1 (enExample)
AU (1) AU553819B2 (enExample)
CA (1) CA1240323A (enExample)
DD (1) DD237658A5 (enExample)
DE (1) DE3571132D1 (enExample)
DK (1) DK463385A (enExample)
EG (1) EG17673A (enExample)
FI (1) FI82044C (enExample)
GR (1) GR852457B (enExample)
HU (1) HU193348B (enExample)
IE (1) IE58722B1 (enExample)
IL (1) IL76644A0 (enExample)
NO (1) NO854033L (enExample)
NZ (1) NZ213743A (enExample)
PH (1) PH21594A (enExample)
PL (1) PL255696A1 (enExample)
PT (1) PT81279B (enExample)
SU (1) SU1375136A3 (enExample)
YU (1) YU44897B (enExample)
ZA (1) ZA857785B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812455A (en) * 1984-10-11 1989-03-14 Pfizer Inc. Antiinflammatory compositions and methods
US5260333A (en) * 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
AU5840200A (en) * 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
AU783855B2 (en) 1999-08-24 2005-12-15 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
WO2001064692A1 (en) 2000-02-29 2001-09-07 Medicure International Inc. Cardioprotective phosphonates and malonates
JP2003528146A (ja) 2000-03-28 2003-09-24 メディキュア インターナショナル インコーポレイテッド 脳血管疾患の治療
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
DE60128912T9 (de) 2000-07-07 2008-06-26 Medicure International Inc. Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
EP1773370A1 (en) * 2004-07-07 2007-04-18 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
JP2008517956A (ja) * 2004-10-28 2008-05-29 メディキュア・インターナショナル・インコーポレーテッド 二重の抗血小板性/抗凝固性ピリドキシン類似体
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
AU2006317440A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230717A (en) * 1978-12-29 1980-10-28 Lovelace Alan M Administrator Indomethacin-antihistamine combination for gastric ulceration control
US4374843A (en) * 1980-10-14 1983-02-22 Pfizer Inc. 2-Guanidino-4-heteroarylthiazoles
US4434163A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Water-soluble benzothiazine dioxide salts
BE894286A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire systemique non steroidique et du 1-methyl-5-((3-(3-(1-piperidinylmethyl)phenoxy)-propyl)amino -1h-1,2,4-triazole-3-methanol ou un sel de ce compose
CY1398A (en) * 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents

Also Published As

Publication number Publication date
CN1008062B (zh) 1990-05-23
JPH0442387B2 (enExample) 1992-07-13
GR852457B (enExample) 1986-02-11
FI853946A0 (fi) 1985-10-10
AU553819B2 (en) 1986-07-31
CA1240323A (en) 1988-08-09
FI82044C (fi) 1991-01-10
AU4848485A (en) 1986-04-17
HU193348B (en) 1987-09-28
ATE44147T1 (de) 1989-07-15
ZA857785B (en) 1987-05-27
PH21594A (en) 1987-12-11
SU1375136A3 (ru) 1988-02-15
DK463385D0 (da) 1985-10-10
CN85107498A (zh) 1986-07-02
IE852498L (en) 1986-04-11
JPS6193182A (ja) 1986-05-12
EG17673A (en) 1990-08-30
PT81279A (en) 1985-11-01
PL255696A1 (en) 1986-07-29
DD237658A5 (de) 1986-07-23
US4567179A (en) 1986-01-28
IL76644A0 (en) 1986-02-28
NO854033L (no) 1986-04-14
FI82044B (fi) 1990-09-28
KR860003248A (ko) 1986-05-21
DK463385A (da) 1986-04-12
DE3571132D1 (en) 1989-07-27
EP0178124A1 (en) 1986-04-16
IE58722B1 (en) 1993-11-03
NZ213743A (en) 1988-11-29
PT81279B (pt) 1988-02-17
HUT38539A (en) 1986-06-30
FI853946L (fi) 1986-04-12
YU44897B (en) 1991-04-30
EP0178124B1 (en) 1989-06-21
YU161685A (en) 1987-12-31

Similar Documents

Publication Publication Date Title
KR870000277B1 (ko) 피록시캄염의 제조방법
US3974281A (en) 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use
US4052509A (en) Method for reducing serum uric acid levels
US4616025A (en) Thiazolidine derivatives, process for the preparation and pharmaceutical compositions thereof
DE69108913T2 (de) 4-alkylimidazolderivate.
JPS6246547B2 (enExample)
JPS59501717A (ja) アシルグアニジン類
JPH0313235B2 (enExample)
EP0105703B1 (en) Dioxocyclobutene compounds
US4388317A (en) Pyrimidones having histamine H2 -antagonist activity
HU198454B (en) Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
CH645368A5 (de) 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)benzoesaeure-derivate sowie verfahren zu deren herstellung.
US4220645A (en) Chromone derivatives
JPS58501468A (ja) 複素環アミジノ置換尿素およびそれらの薬剤利用
HU192875B (en) Process for preparing 2-pyridinethiol derivatives
JPS6310701B2 (enExample)
WO1984004304A1 (en) Aminoimidazolone derivatives as histamine h2-antagonists
EP0178822B1 (en) 2-guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis
US3760082A (en) Compositions containing 5-amino-3-ethyl-1-phenyl-4-pyrazolecarboxamides and methods of using the same
US3502724A (en) P-chloro-n-(chloropropyl)-alpha-methyl-phenethylamines and the salts thereof
JPS58170779A (ja) ピリジン誘導体
US3708581A (en) Anti-inflammatories
JP2619286B2 (ja) 抗胃炎・抗消化性潰瘍剤
DE3105121A1 (de) Neue piperazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung
KR870000924B1 (ko) 2-(n-치환된 구아니디노)-4-헤테로아릴티아졸의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 19931210

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19950224

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19950224

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000